NCT00866138 2019-12-03Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3AB SciencePhase 2 Completed24 enrolled
NCT01470131 2018-12-19A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaAB SciencePhase 3 Terminated147 enrolled